50% Off! Beat the market in 2025 with InvestingProCLAIM SALE

J&J Raises Forecast For 2021 Sales, EPS As Pharma, Devices Grow

Published 04/20/2021, 07:40 AM
Updated 04/20/2021, 07:42 AM
© Reuters.
JNJ
-

By Dhirendra Tripathi

Investing.com – Johnson & Johnson (NYSE:JNJ) on Tuesday raised its guidance for both sales and earnings per share after reporting healthy growth in its medical devices and pharmaceutical businesses.

The company also saw the first $100 million in revenue from its Covid-19 shots.

J&J shares were down 0.4% in premarket, weighed by the concerns surrounding its Covid-19 vaccine, whose sales remain suspended after some cases of rare blood clotting were reported a few days ago.

The company increased its 2021 full-year guidance for adjusted operational sales growth to 9.3% and adjusted operational EPS growth to 16.8% at the midpoint.

In the forecast given on January 26, operational sales growth was seen to be 8.8% and adjusted operational EPS growth was expected to come at 16.4% in 2021.

The company reported first quarter sales of $22.32 billion, the 7.9% growth driven by 9.6% sales growth in the pharmaceutical segment and 10.9% jump in medical devices business.

Adjusted first quarter EPS of $2.59 increased 12.6% from a year earlier.

 

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.